Peanut immunotherapy

Clinical and Translational Allergy

Andrew Clark¹  Katherine Anagnostou² 

[1] Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Box 157, Cambridge CB2 0QQ, UK;Department of Paediatric Allergy, Guy’s and St Thomas’ Hospitals NHS Foundation Trust, Westminster Bridge Road, London, UK

关键词: Immunotherapy;    Peanut;    Allergy;   

Others  :  1092761
DOI  :  10.1186/2045-7022-4-30

 received in 2014-08-05, accepted in 2014-09-05,  发布年份 2014

【 摘 要 】

Peanut allergy is common and can be a cause of severe, life-threatening reactions. It is rarely outgrown like other food allergies, such as egg and milk. Peanut allergy has a significant effect on the quality of life of sufferers and their families, due to dietary and social restrictions, but mainly stemming from fear of accidental peanut ingestion. The current management consists of strict avoidance, education and provision of emergency medication, but a disease- modifying therapy is needed for peanut allergy. Recent developments involve the use of immunotherapy, which has shown promise as an active form of treatment. Various routes of administration are being investigated, including subcutaneous, oral, sublingual and epicutaneous routes. Other forms of treatment, such as the use of vaccines and anti-IgE molecules, are also under investigation. So far, results from immunotherapy studies have shown good efficacy in achieving desensitisation to peanut with a good safety profile. However, the issue of long-term tolerance has not been fully addressed yet and larger, phase III studies are required to further investigate safety and efficacy. An assessment of cost/benefit ratio is also required prior to implementing this form of treatment. The use of immunotherapy for peanut allergy is not currently recommended for routine clinical use and should not be attempted outside specialist allergy units.

【 授权许可】

   
2014 Anagnostou and Clark; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bock SA, Muñoz-Furlong A, Sampson HA: Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001, 107:191-193. Jan [cited 2010 Jul 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11150011 webcite
• [2]Hourihane JO, Aiken R, Briggs R, Gudgeon LA, Grimshaw KEC, DunnGalvin A, Roberts SR: The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry. J Allergy Clin Immunol 2007, 119(5):1197-1202. May [cited 2011 Feb 15]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17353036 webcite
• [3]Pereira B, Venter C, Grundy J, Clayton CB, Arshad SH, Dean T: Prevalence of sensitization to food allergens, reported adverse reaction to foods, food avoidance, and food hypersensitivity among teenagers. J Allergy Clin Immunol 2005, 116(4):884-892. Oct [cited 2011 Mar 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16210065 webcite
• [4]Venter C, Hasan Arshad S, Grundy J, Pereira B, Bernie Clayton C, Voigt K, Higgins B, Dean T: Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. Allergy 2010, 65(1):103-108. Blackwell Publishing Ltd. Available from: http://dx.doi.org/10.1111/j.1398-9995.2009.02176.x webcite
• [5]Sampson HA, Mendelson L, Rosen JP: Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992, 327(6):380-384. Massachusetts Medical Society; [cited 2011 Mar 14]. Available from: http://www.nejm.org/doi/pdf/10.1056/NEJM199208063270603 webcite
• [6]Vadas P, Perelman B: Presence of undeclared peanut protein in chocolate bars imported from Europe. J Food Prot 2003, 66(10):1932-1934. Available from: http://pubget.com/paper/14572236 webcite
• [7]Schäppi GF, Konrad V, Imhof D, Etter R, Wüthrich B: Hidden peanut allergens detected in various foods: findings and legal measures. Allergy 2001, 56(12):1216-1220. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11736754 webcite
• [8]Avery NJ, King RM, Knight S, Hourihane JOB: Assessment of quality of life in children with peanut allergy. Pediatr Allergy Immunol 2003, 14(5):378-382. Wiley Online Library. Available from: http://onlinelibrary.wiley.com/doi/10.1034/j.1399-3038.2003.00072.x/full webcite
• [9]Primeau MN, Kagan R, Joseph L, Lim H, Dufresne C, Duffy C, Prhcal D, Clarke A: The psychological burden of peanut allergy as perceived by adults with peanut allergy and the parents of peanut-allergic children. Clin Exp Allergy 2000, 30(8):1135-1143. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10931121 webcite
• [10]Bock SA, Atkins F: The natural history of peanut allergy 1. J Allergy Clin Immunol 1989, 83(5):900-904. Elsevier. Available from: http://linkinghub.elsevier.com/retrieve/pii/0091674989901036 webcite
• [11]Hourihane JO, Roberts SA, Warner JO: Resolution of peanut allergy: case–control study. BMJ 1998, 316(7140):1271-1275. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=28527&tool=pmcentrez&rendertype=abstract webcite
• [12]Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA: The natural history of peanut allergy. J Allergy Clin Immunol 2001, 107(2):367-374. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11174206 webcite
• [13]Ho MHK, Wong WHS, Heine RG, Hosking CS, Hill DJ, Allen KJ: Early clinical predictors of remission of peanut allergy in children. J Allergy Clin Immunol 2008, 121(3):731-736. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18234313 webcite
• [14]Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341(7):468-475. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20109743 webcite
• [15]Calderon M, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, (1):CD001936. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001936.pub2/pdf/standard webcite
• [16]Wilson DR, Lima MT, Durham SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005, 60(1):4-12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15575924 webcite
• [17]Ross RN, Nelson HS, Finegold I: Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther 2000, 22(3):351-358. Available from: http://www.sciencedirect.com/science/article/pii/S0149291800800399 webcite
• [18]Graft D, Schuberth K: Assessment of prolonged venom immunotherapy in children. J Allergy Clin Immunol 1987, 80(2):162-169. Available from: http://www.sciencedirect.com/science/article/pii/0091674987901254 webcite
• [19]Valentine M, Schuberth KC, Kagey-Sobotka A, Graft DF, Kwiterovich KA, Szklo M, Lichtenstein LM: The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990, 323(23):1601-1603. Available from: http://www.nejm.org/doi/full/10.1056/NEJM199012063232305 webcite
• [20]Golden D, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM: Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004, 351(7):668-674. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa022952 webcite
• [21]Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, Ventura A: Specific oral tolerance induction in children with very severe cow’s milk-induced reactions. J Allergy Clin Immunol 2008, 121(2):343-347. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2007.01501.x/full webcite
• [22]Brożek JL, Terracciano L, Hsu J, Kreis J, Compalati E, Santesso N, Fiocchi A, Schünemann HJ: Oral immunotherapy for IgE-mediated cow’s milk allergy: a systematic review and meta-analysis. Clin Exp Allergy 2012, 42(3):363-374. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22356141 webcite
• [23]Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, Stablein D, Henning AK, Vickery BP, Liu AH, Scurlock AM, Shreffler WG, Plaut M, Sampson HA, Consortium of Food Allergy Research (CoFAR): Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 2012, 367(3):233-243. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22808958 webcite
• [24]Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY: Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992, 90(2):256-262.
• [25]Nelson HS, Lahr J, Rule R, Bock A, Leung D: Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997, 99(6, Part 1):744-751. Available from: http://www.sciencedirect.com/science/article/B6WH4-4K19H2S-6/2/9f9ece271b5aa1b5439e7e42251aba93 webcite
• [26]Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW: Successful oral tolerance induction in severe peanut allergy. Allergy 2009, 64(8):1218-1220. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19226304 webcite
• [27]Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P: Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 2011, 41(9):1273-1281. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21414048 webcite
• [28]Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, Shreffler WG, Steele P, Henry KA, Adair M, Francis JM, Durham S, Vickery BP, Zhong X, Burks AW: Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009, 124(2):292-300, 300.e1-97. Elsevier Ltd. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2725434&tool=pmcentrez&rendertype=abstract webcite
• [29]Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, Hiegel A, Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B, Burks W: A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011, 127(3):654-660. Elsevier Ltd. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21377034 webcite
• [30]Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, Palmer C, Deighton J, Ewan P, Clark A: Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014, 6736(Stop Ii):1-8. Anagnostou et al. Open Access article distributed under the terms of CC BY-NC-ND. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24485709 webcite
• [31]Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, Steele P, Kamilaris J, Vickery B, Burks AW: Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011, 127(3):640-646.e1. Elsevier Ltd. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21281959 webcite
• [32]Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, Sicherer SH, Liu AH, Stablein D, Henning AK, Mayer L, Lindblad R, Plaut M, Sampson H: Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2014, 131(1):119-127.e7. Elsevier. Available from: http://www.jacionline.org/article/S0091-6749(12)01824 webcite-6/abstract
• [33]Senti G, von Moos S, Kündig TM: Epicutaneous immunotherapy for aeroallergen and food allergy. Curr Treat Options Allergy 2014, 1:68-78. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4025904&tool=pmcentrez&rendertype=abstract webcite
• [34]Dupont C, Kalach N, Soulaines P, Legoué-Morillon S, Piloquet H, Benhamou P-H: Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010, 125(5):1165-1167. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20451043 webcite
• [35]Wood RA, Sicherer SH, Burks AW, Grishin A, Henning AK, Lindblad R, Stablein D, Sampson HA: A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy 2013, 68(6):803-808. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3663889&tool=pmcentrez&rendertype=abstract webcite
• [36]Leung DYM, Sampson HA, Yunginger JW, Burks AW, Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR Jr, Avon Longitudinal Study of Parents and Children Study Team: Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003, 348(11):986-993. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14700433 webcite
• [37]Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT: A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 2013, 132(6):1368-1374. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24176117 webcite
• [38]Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LCL, Shreffler WG, Sampson HA, Niggemann B, Wahn U, Beyer K: Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 2010, 126(1):83-91.e1. Elsevier Ltd. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20542324 webcite
• [39]Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, Perry TT, Pesek RD, Sheikh S, Virkud Y, Smith PB, Shamji MH, Durham SR, Jones SM, Burks AW: Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol 2014, 133(2):468-475. Elsevier Ltd. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24361082 webcite
• [40]Syed A, Garcia MA, Lyu S-C, Bucayu R, Kohli A, Ishida S, Berglund JP, Tsai M, Maecker H, O’Riordan G, Galli SJ, Nadeau KC: Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol 2014, 133(2):500-510. Elsevier Ltd. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24636474 webcite
• [41]Varshney P, Jones SM, Pons L, Kulis M, Steele PH, Kemper AR, Steele P, Hiegel A, Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B, Burks AW: Oral immunotherapy (OIT) induces clinical tolerance in peanut-allergic children. J Allergy Clin Immunol 2009, 123(2, Supplement 1):S174-S174. Available from: http://www.sciencedirect.com/science/article/B6WH4-4VK8XCP-VB/2/0f2f1dbfefe726176b9e642b62f558b5 webcite
• [42]Nurmatov U, Venderbosch I, Devereux G, Fer S, Sheikh A: Allergen-specific oral immunotherapy for peanut allergy (Review). Cochrane Database Syst Rev 2012, (9):CD009014. doi:10.1002/14651858.CD009014.pub2